ANXA1 and COVID-19: Furthermore, the broad spectrum immunosuppressant drug dexamethasone treatment given to critically ill COVID-19 patients may be associated with the risk of venous thromboembolism because corticosteroids are known to induce anti-inflammatory AnxA1, recruiting to the membrane surface results in lowered translocation of AnxA2 to the cell membrane, which could precipitate into thrombosis [119].